Advertisement

Topics

Companies Related to "Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure." [Most Relevant Company Matches] RSS

22:31 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure." found in our extensive corporate database of over 50,000 company records.

Showing "Fondaparinux Anticoagulant Haemofiltration Patients With Acute Kidney Failure" Companies 1–25 of 4,300+

Extremely Relevant

Alchemia Limited

The Company’s lead program is fondaparinux (a generic version of GlaxoSmithKline’s Arixtra®, a synthetic anticoagulant mainly used for the prevention of deep vein thrombosis). The ANDA for generic fondaparinux was filed for approval with the US FDA in March 2009 and approval is pending. It is partnered with Dr Reddy’s Laboratories for glo...


NephRx Corporation

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical dev...

RenaMed Biologics, Inc

RenaMed Biologics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. RenaMed’s products are designed to dramatically improve the clinical outcome and cost of care for patients suffering from Acute Renal Failure and additional indications where kidney function is compromised...


Relevant

DaVita Inc.

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services and education to patients with chronic kidney failure and end stage renal disease. As of March 31, 2010, DaVita operated or provided administrative services at 1,544 outpatient dialysis facilities, serving approximately 119,000 pa...

The Kidney TRUST

Founded in 2006, the TRUST is a non-profit organization dedicated to reducing the human and economic cost of kidney disease. The TRUST is focused on increasing awareness of chronic kidney disease (CKD) through public education and testing programs so that progression of CKD to kidney failure can be delayed or prevented. The TRUST is also developing innovative solutions to address the critical un...

MedaSorb Technologies

MedaSorb Technologies (“MedaSorb” or the “Company) has developed a new platform technology that efficiently removes toxic compounds from the bloodstream. Current state-of-the-art blood purification techniques are not designed for this purpose and are inefficient at removing these toxins. The Company’s products, which incorporate a proprietary adsorbent polymer technology, are known medical...

Thrasos Therapeutics

Thrasos TherapeuticsTM is a private, clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease. The Company is advancing therapeutic programs, led by THR-184, for renal diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). Thrasos’...

Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. The initial focus of the Company is the prevention of acute kidney injury and cardiac injury in patients undergoing cardiac catheterization procedures. Ischemix’ lead product...

RenalTech International LLC

RenalTech is dedicated to developing new and innovative technologies to potentially improve the quality of life for chronic renal (kidney) failure patients worldwide.

Nuvelo

Nuvelo, Inc. is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thr...

Kibow Biotech Inc

Kibow Biotech Inc. was founded in 1997 by Dr. N. Ranganathan and Dr. Jack Dickstein. Kibow Biotech Inc. started out to fill the void in treatments for patients with chronic kidney disease. Since then Kibow Biotech Inc. has been actively researching on ways and methods to develop a cost-effective non-invasive treatment for kidney disease patients. This has since became our mission statement. The co...

U.S. Renal Care, Inc.

Founded in 2000 by an experienced team of healthcare executives, U.S. Renal Care, Inc. works in partnership with nephrologists to develop, acquire, and operate outpatient treatment centers for persons suffering from chronic kidney failure, also known as End Stage Renal Disease. The company provides patients with their choice of a full range of quality in-center, acute or at-home hemodialysis and p...

NxStage Medical Inc.

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

DaVita, Inc.

DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and con...

A1M Pharma

A1M Pharma develops a diagnostic method and a novel treatment for the damaging effects of pre-eclampsia, a condition that affects around 10 million pregnant women worldwide. This disorder is responsible for 76,000 maternal and 500,000 infant deaths each year. It is also the cause of 15 per cent of all premature births. Currently, there is no predictive diagnostic method or treatment for impairme...

Renal Ventures Management LLC

Renal Ventures Management LLC is a leading provider of dialysis services in the U.S. The company partners with hospitals and physicians to provide patients suffering from chronic kidney failure with knowledgeable, compassionate and quality-focused care in comfortable clinic settings. For its hospital and nephrologist partners, Renal Ventures Management pro...

ALung Technologies, Inc.

ALung Technologies, Inc. is commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. The company's Hemolung System, designed to replace or supplement the use of ventilators for patients with acute respiratory failure, is scheduled to begin clinical trials in the fall of 2009. Learn more about ALung and Hemolung at www.alung.com.

Miracor Medical Systems GmbH

Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO® as the standard of care for heart attack patients, thereby improving their quality of life. The ...

The Centre of Excellence for the Prevention of Organ Failure

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) develops blood tests to diagnose, treat and manage heart, lung and kidney disease. The PROOF Centre is a cross-disciplinary engine of partners representing academia, health care, government, industry, patients and the public, to improve heart, lung and kidney health and reduce the ...

Promise Healthcare, Inc.

Based in Boca Raton, Florida, Promise Healthcare is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 2,000 staff members and 13 hospitals nationwide, Promise Hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive LTAC environment provides acute medical care and ...

DaVita HealthCare Partners

DaVita HealthCare Partners, a Fortune 500® company, is the parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1...

DaVita HealthCare Partners Inc.

DaVita HealthCare Partners, a Fortune 500® company, is the parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1...

Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002, an ammonia detoxification agent, for the treatment of hospitalized patients wit...

Promise Healthcare

Headquartered in Boca Raton, Florida, Promise Healthcare, Inc. (www.promisehealthcare.com) is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 5,000 staff members and 19 health care facilities nationwide, Promise hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive ...

ORQIS Medical Corporation

ORQIS Medical Corporation is a privately held, medical device company developing its discovery of a novel approach to treat the underlying mechanisms responsible for congestive heart failure. ORQIS Medical discovered that continuous aortic flow augmentation (CAFA), blood flow augmentation specifically in the descending aorta, may correct abnormal circulatory conditions associated with heart failur...


More From BioPortfolio on "Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure."

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks